Soligenix announces strategic partnership with serb pharmaceuticals to supply its novel ricin antigen

Serb pharmaceuticals pursuing therapeutic treatment  against ricin poisoning using soligenix ricin antigen princeton, n.j. , july 25, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has signed a worldwide exclusive license to supply its ricin antigen to serb pharmaceuticals (serb), for development of a novel therapeutic treatment against ricin toxin poisoning.
SNGX Ratings Summary
SNGX Quant Ranking